IsoRay (NYSEAMERICAN:ISR) has been assigned a $2.00 price target by equities research analysts at Maxim Group in a research note issued to investors on Wednesday. The firm presently has a “buy” rating on the healthcare company’s stock. Maxim Group’s price objective suggests a potential upside of 344.44% from the stock’s previous close.
Shares of IsoRay (ISR) traded up $0.01 during trading on Wednesday, reaching $0.45. The company had a trading volume of 61,566 shares, compared to its average volume of 147,928. IsoRay has a 1-year low of $0.38 and a 1-year high of $0.69. The firm has a market cap of $25.35, a price-to-earnings ratio of -4.09 and a beta of 1.11.
IsoRay (NYSEAMERICAN:ISR) last announced its earnings results on Thursday, February 8th. The healthcare company reported ($0.03) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01). IsoRay had a negative net margin of 95.25% and a negative return on equity of 69.11%. The firm had revenue of $1.54 million during the quarter.
WARNING: “IsoRay (ISR) Given a $2.00 Price Target at Maxim Group” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/14/isoray-isr-given-a-2-00-price-target-at-maxim-group.html.
IsoRay Company Profile
IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.